MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Substantia nigra"

  • 2026 International Congress

    Delayed Parkinsonism Following Japanese Encephalitis: A Case Report with Dopamine Transporter Imaging and L-dopa/DCI treatment

    R. Yui, Y. Kobayashi, G. Okumura, M. Katagiri, C. Yuzawa, Y. Shimizu (Ina, Japan)

    Objective: To report a case of Japanese encephalitis (JE) presenting with thalamic–midbrain lesions followed by delayed parkinsonism confirmed by dopamine transporter imaging. Background: JE is…
  • 2026 International Congress

    The Dual Functional Organization of the Substantia Nigra in Parkinson’s Disease

    M. Passaretti, D. Vereb, B. Zufiria-Gerbolés, M. Mijalkov, M. Veronese, J B. Pereira (Stockholm, Sweden)

    Objective: We applied connectopic mapping to the internal functional organisation of the substantia nigra (SN) in independent cohorts. Background: The human SN is a central…
  • 2026 International Congress

    Association of Neurofilament Light Chain with Substantia Nigra Degeneration in Parkinson’s Disease

    WJ. Wu, WQ. Jiang, QY. Zheng, L. Luo, Y. Zhang, XY. Zhang, ZM. Dong, ZY. Yu, T. Wu, XJ. Dai, DL. Zhang (Beijing, China)

    Objective: This study aims to investigate the association between serum neurofilament light chain (NfL), microstructural changes in the substantia nigra, and clinical manifestations in Parkinson’s…
  • 2025 International Congress

    Modeling Levodopa Resistance in Parkinson’s Disease: A Novel Approach Targeting Locus Coeruleus Degeneration

    A. Goel, R. Goel (Bathinda, India)

    Objective: To develop a Parkinson’s disease (PD) model replicating levodopa (LD) resistance by incorporating degeneration of both the substantia nigra (SN) and locus coeruleus (LC),…
  • 2025 International Congress

    Profiling Neural Protein Dopaminylation in Parkinson’s disease

    W. Chen, I. Maze (NEW YORK, USA)

    Objective: The hallmark of Parkinson’s Disease is motor dysfunction from the decline in dopaminergic cells in the substantia nigra (SN), leading to the development of…
  • 2025 International Congress

    Transcranial sonography in Parkinson’s disease patients

    D. Khasanova, I. Khasanov, Z. Zalyalova (Kazan, Russian Federation)

    Objective: To present the usage and results of transcranial sonography (TCS) in Parkinson's disease (PD) patients. Background: (TCS) has emerged as a valuable diagnostic tool…
  • 2025 International Congress

    Histopathology of long-term implants of peripheral nerve tissue into the substantia nigra of patients with Parkinson’s disease

    J. Quintero, A. Marlonsson, A. Granholm, G. Gerhardt, C. van Horne (Lexington, USA)

    Objective: To characterize autologous peripheral nerve tissue (PNT) implants into the substantia nigra of individuals with PD who participated in our previous clinical trials. Background:…
  • 2025 International Congress

    Predictors of Clinical Benefit from Adaptive DBS Compared to Conventional DBS in Parkinson’s Disease

    J. Tanimura, T. Hashimoto (Matsumoto, Japan)

    Objective: To identify patient characteristics predicting adaptive deep brain stimulation (aDBS) superiority over conventional DBS (cDBS) in Parkinson's disease (PD). Background: Adaptive DBS, modulated in…
  • 2024 International Congress

    Concordance of Neuropathologic Diagnosis of Lewy Body Disease with Baseline Alpha-Synuclein Seed Amplification Assay in PPMI

    K. Poston, J. Ha, T. Montine, S. Bukhari, T. Foroud, L. Heathers, K. Nudelman, I. Aldecoa, A. Garrido, J. Franz, C. Stadelmann, J-P. Vonsattel, A. Siderowf, L. Chahine, T. Simuni, K. Marek (Stanford, USA)

    Objective: To determine whether the alpha-synuclein seed amplification assay (aSyn-SAA) performed on cerebral spinal fluid (CSF) collected at the baseline (BL) PPMI visit is concordant…
  • 2024 International Congress

    TM9SF2 Knockdown Decreases Pathological Alpha-synuclein Aggregation In Vivo

    C. Sortwell, R. Kumaran, F. Manfredsson, C. Kemp, M. Benskey, J. Patterson, A. Stoll, J. Howe, N. Kuhn, K. Luk, M. Cookson (Grand Rapids, USA)

    Objective: To determine whether knockdown of transmembrane 9 super family 2 (TM9SF2) decreases the formation of alpha-synuclein inclusions and toxicity to nigral neurons in the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley